Epi-Minder and the University of Melbourne
Made possible, together
Improving lives through collaboration
We work across health, engineering, business and the arts with organisations whose strategic objectives align with ours. We're committed to long-term partnerships that are based on trust, openness and shared goals. As a partner, you’ll have access to the infrastructure and resources that translate ideas into impact.
From developing new medical devices through to enhancing treatments for widespread illnesses, we can partner on all things biomedical – bringing together multidisciplinary experts, healthcare centres and communities to ensure we create real impact.
Our partnership with Epi-Minder is on the path to making it easier for people living with epilepsy to carry out everyday activities.
Seizure-detecting device undergoes clinical trial
The unpredictability of seizures means that people living with epilepsy may be unable to work or drive. Based on years of research in neuroscience and electrical engineering, Epi-Minder – which was co-founded by University of Melbourne researchers – has developed an implantable device that can monitor the brain’s electrical activity to detect epileptic seizures. Currently undergoing a clinical trial, the device would make it easier for people with epilepsy to carry out everyday activities and benefit their safety, mental health and employability. Established in 2018, Epi-Minder has raised A$44 million to further develop and commercialise the seizure detection device.
- Impact: People living with epilepsy would find it easier to carry out everyday activities
- Innovation: Minder – an epilepsy management device that reliably predicts seizures
- Partners: Cochlear Ltd, The Bionics Institute, St Vincent’s Hospital Melbourne
- Partnership approach: University of Melbourne start-up with investor partners
The University of Melbourne, together with its partners, has made possible the potential to help 50 million people living with epilepsy worldwide to feel safe, confident and in control. After raising A$18 million in funding from investors in 2020, medical and engineering experts have teamed up to develop Minder, a small implantable device designed to detect and predict epileptic seizures.
Our MedTech program provides the pathway to bring new technologies into real-world healthcare applications .
Whether you have a specific challenge to overcome, or you’re interested in finding out about potential opportunities for your organisation to collaborate with us, get in touch now to start a conversation.